Astell&Kern has taken all the best from its high-resolution portable audio players and created a new, all-in-one monolith of sound called the AKT1. Skip to main content Menu ...

Akt1 through the C-terminal domain interacts with the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and stimulates the repair of DNA double-strand breaks (DSBs) in K-RAS-mutated (K ...

So I think that this leaves open the question of what to do with AKT inhibitors in metastatic breast cancer. Of course here in metastatic triple-negative breast cancer, I don't know that the story ...

Mutation causes changes in the binding domain of the enzyme. Researchers from Eli Lilly and the Translational Genomics Research Institute (TGen) discovered a novel recurring mutation of the gene ...

Publisher’s Note. The July 10, 2017, article by Hyman et al entitled “AKT Inhibition in Solid Tumors With AKT1 Mutations” (J Clin Oncol 35:2251-2259, 2017) was published online May 10, 2017, with ...

San Diego–based Alterome Therapeutics is advancing two lead drug candidates in parallel. One goes after the oncogene AKT1, whose E17K-mutated form can lead to breast and gynecologic cancers.

Several recent Atavistik Bio Inc. patents describe substituted aminopyridine compounds acting as RAC-α serine/threonine-protein kinase (AKT1; PKBα) inhibitors, particularly AKT1 (E17K mutant) reported ...

Data demonstrate that ATV-1601, a selective allosteric inhibitor of AKT1 E17K, provides enhanced target inhibition, superior efficacy and improved tolerability compared to pan-AKT inhibitors in ...

Atavistik Bio Inc. has nominated an orally bioavailable selective allosteric AKT1 E17K inhibitor, ATV-1601, as a development candidate for AKT1 E17K-driven cancers.

In patients with AKT1 E17K–mutant tumors (n = 52) and a median of five lines of prior therapy, the median PFS was 5.5 months (95% CI, 2.9 to 6.9 months), 6.6 months (95% CI, 1.5 to 8.3 months), and ...